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Lowering the levels of disease-causing proteins is an attractive treatment strategy for neurodegenerative disorders, among which
Huntington’s disease is an appealing disease for testing this strategy because of its monogenetic nature. Huntington’s disease is
mainly caused by cytotoxicity of the mutant HTT protein with an expanded polyglutamine repeat tract. Lowering the soluble
mutant HTT may reduce its downstream toxicity and provide potential treatment for Huntington’s disease. This is hard to achieve
by small-molecule compound drugs because of a lack of effective targets. Here we demonstrate Gpr52, an orphan G protein-
coupled receptor, as a potential Huntington’s disease drug target. Knocking-out Gpr52 signiﬁcantly reduces mutant HTT levels in
the striatum and rescues Huntington’s disease-associated behavioural phenotypes in a knock-in Huntington’s disease mouse model
expressing endogenous mutant Htt. Importantly, a novel Gpr52 antagonist E7 reduces mutant HTT levels and rescues
Huntington’s disease-associated phenotypes in cellular and mouse models. Our study provides an entry point for Huntington’s
disease drug discovery by targeting Gpr52.
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Abbreviations: DMSO = dimethyl sulfoxide; GPCR = G protein-coupled receptor; hGpr52 = human Gpr52; HTRF = homoge-
neous time resolved ﬂuorescence; iPSC = induced pluripotent stem cell; mHTT = mutant HTT
Introduction
Neurodegenerative disorders, characterized by progressive
loss of neurons in the CNS, inﬂuence millions of people in
the aged population. Treatment of such diseases has been
extremely challenging, and there is currently no disease pro-
gression-modifying treatment. A common hallmark for these
diseases is the accumulation of misfolded and aggregation-
prone proteins, and lowering their levels is considered as an
appealing therapeutic strategy (Soto, 2003). Among differ-
ent neurodegenerative disorders, the monogenetic disorder
Huntington’s disease provides appealing genetic models to
study the disease-protein lowering strategy, because the gen-
etics and the disease-causing protein is clear. Huntington’s
disease is caused by the mutation of the HTT gene encoding
the mutant HTT protein (mHTT) with expanded polygluta-
mine tract (polyQ) (The Huntington’s Disease Collaborative
Research Group, 1993). Lowering the mHTT level amelior-
ates mHTT toxicity in multiple models. In a transgenic
Huntington’s disease mouse model expressing inducible
mHTT N-terminal fragments, turning off the transgene re-
versed neuropathology and motor deﬁcits (Yamamoto et al.,
2000). Delivery of short hairpin RNAs (shRNAs), small
interference RNAs (siRNAs) or antisense oligonucleotides
reducing mHTT attenuate neuropathology and disease-
related phenotypes in several mouse models (Harper et al.,
2005; Rodriguez-Lebron et al., 2005; DiFiglia et al., 2007;
Kordasiewicz et al., 2012). CRISPR/Cas9-mediated genome
editing of mHTT ameliorated Huntington’s disease neuro-
toxicity (Yang et al., 2017). Several screening studies re-
vealed that genetic modiﬁers of mHTT levels rescued
Huntington’s disease-associated phenotypes (Zhang et al.,
2010; Baldo et al., 2012; Lu et al., 2013). A clinical trial
using a non-allele speciﬁc antisense oligonucleotide to lower
HTT levels has also been launched for Huntington’s disease
treatment (https://www.clinicaltrials.gov/ct2/show/NCT02
519036). In most studies, both mHTT and the wild-type
HTT were lowered, and beneﬁcial effects were still
observed.
Meanwhile, delivering antisense oligonucleotides, siRNA/
shRNAs or genome editing reagents into patient’s brains is
challenging and expensive, and thus small molecule drugs
that reduce HTT levels are highly desired. This is extremely
challenging because of a lack of reliable drug targets. G
protein-coupled receptors (GPCRs) constitute the largest
drug target family of FDA-approved drugs (Overington
et al., 2006). They are located on the plasma membrane
and modulated by endogenous extracellular molecules,
making them ideal targets for small molecule compounds.
We have previously identiﬁed an orphan GPCR, Gpr52,
as a striatal-enriched modulator of soluble mHTT levels ex
vivo and in vivo (Yao et al., 2015). Knocking-down Gpr52
or loss of function mutation of Gpr52 rescues Huntington’s
disease-associated phenotypes in Huntington’s disease
ﬂy models and patient induced pluripotent stem cell
(iPSC)-derived neurons (Yao et al., 2015). To investigate
its therapeutic potential as a Huntington’s disease drug
target further, we tested its effect in modulating
Huntington’s disease-associated phenotypes in vivo in a
knock-in mouse model, which expresses mHtt (indicating
the mouse mutant HTT protein) from its endogenous
locus. We then discovered a novel Gpr52-speciﬁc small
molecule antagonist E7, and tested the possibility of
lowering soluble mHtt levels and treating Huntington’s
disease via targeting Gpr52 by E7. Our data provide
the proof-of-concept evidence of treating Huntington’s




The overall objective of this study was to test the possibility of
targeting Gpr52 for Huntington’s disease treatment and drug
discovery by in vivo experiments.
To this end, we used Huntington’s disease in vivo knock-in
mouse models and Huntington’s disease in vivo Drosophila
models. In addition, we used the HEK293 stable cell line ex-
pressing hGpr52 was used for compound screening of hGpr52
antagonists.
For validation of Gpr52 per se, Huntington’s disease or
wild-type mice with different genotypes of Gpr52 were tested
for Huntington’s disease-relevant phenotypes and HTT levels,
the animals were allocated by their genotypes and no random-
ization was necessary (Wang et al., 2014). For validation of
Gpr52 antagonist E7, cellular, Drosophila and mouse
Huntington’s disease models were used. For cellular experi-
ments, cells were resuspended and randomly distributed
during plating for each cell type. For Drosophila experiments,
the ﬂies were randomly sorted in the testing tubes for each
type of ﬂy. For mouse experiments, a random number between
0 and 1 was generated for each mouse by Microsoft Excel to
determine the E7 versus dimethyl sulphoxide (DMSO) intra-
cerebroventricular injection (E7: 5 0.5, DMSO: 50.5). The
mouse behavioural experiments were all performed blind, and
the mouse genotypes or drugs delivered were not revealed
before data analysis. For statistical analysis, sufﬁcient sam-
ples/replicates were collected (power4 0.8) and the sample
sizes are comparable or higher than similar studies (Park
et al., 2013). All representative images were repeated multiple
times, and the replication numbers are indicated in the quan-
tiﬁcation and/or ﬁgure legends.
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For detailed experimental procedures and information of
materials in cellular and animal models, refer to the
Supplementary material.
Results
Knockout of Gpr52 rescues beha-
vioural phenotypes in a Huntington’s
disease knock-in mouse model
We have previously demonstrated that lowering Gpr52 res-
cues Huntington’s disease-associated phenotypes in cellular
and Drosophila models (Yao et al., 2015). To investigate
the therapeutic potential of Gpr52 as a Huntington’s disease
drug target further, we tested whether heterozygous or
homozygous knockout of Gpr52 rescues Huntington’s
disease-associated behavioural phenotypes in vivo in mice.
We crossed the Gpr52 knockout mice to a well-established
Huntington’s disease knock-in mouse model expressing
endogenous mHtt proteins with 140Q (HdhQ140/Q140; the
wild-type HTT protein has 7Q) (Menalled et al., 2003).
This model expresses mHtt from its original genomic locus,
and thus has high ﬁdelity to human Huntington’s disease
patients in the aspects of disease genetics and mHtt protein
levels. In addition, mHtt expression in this model does not
lead to weight changes (Menalled et al., 2003), minimizing
potential artefacts due to weight differences.
Consistent with other groups (Menalled et al., 2003; Hickey
et al., 2012), we observed several motor function-related def-
icits in the homozygous Huntington’s disease (HdhQ140/Q140)
mice, including less activity (measured by the frequency of
rearing) in a pen holder with mashed surface, locomotion
deﬁcits in the open-ﬁeld, abnormal gait behaviours and
rotarod deﬁcits (Figs 1 and 2). Meanwhile, using the hetero-
zygous Huntington’s disease mice (HdhQ7/Q140) at similar
ages, the Huntington’s disease-associated behavioural pheno-
types were much less reliable and failed to give us a sufﬁcient
window to test potential rescue effects (Yu et al., 2017), and
thus we tested Gpr52’s effects mainly in homozygous
Huntington’s disease mice.
We performed power analysis based on the effect size
and variation estimated by our preliminary and previously
published studies, and determined that at least ﬁve mice
were needed for each group to reach a statistical
power4 0.8. We also calculated the post-experiment
powers for all the experiments showing signiﬁcance to
ensure sufﬁcient statistical power (indicated above each
ﬁgure panel). The number of mice used for each group is
similar or higher than similar studies from other groups
(Park et al., 2013; Wang et al., 2014; Ochaba et al., 2016).
By crossing the Gpr52 knockouts to the Huntington’s dis-
ease mice for several generations, we obtained both Gpr52
heterozygous (Gpr52+ /) and homozygous (Gpr52/)
knockout versus housemate controls (Gpr52+ / + ) in the
Huntington’s disease (HdhQ140/Q140) as well as wild-type
(HdhQ7/Q7) background. In the open ﬁeld tests, Gpr52 homo-
zygous knockout signiﬁcantly (P5 0.05) rescued deﬁcits in
the travel distance and the cross-number measurements at the
age of 7.5 and 10 months, and the Gpr52 heterozygous
knockout also had a similar effect (Fig. 1A and B, the right
three bars of each panel). At the age of 13.5 months,
Huntington’s disease mice also developed a signiﬁcant low-
ering of the ratio between the travel distance in the central
versus the peripheral region (Fig. 1C, right), suggesting an
increased anxiety level of Huntington’s disease mice com-
pared to the wild-type mice. This phenotype was not
observed at younger ages (Fig. 1A and B, right), suggesting
that Huntington’s disease mice develop psychological pheno-
types in addition to motor deﬁcits at later ages, consistent
with Huntington’s disease human patients. At the age of 13.5
months, Gpr52 knockout signiﬁcantly rescued the
Huntington’s disease-associated phenotypes in the travel dis-
tance, cross number and central/peripheral ratio in the open-
ﬁeld tests (Fig. 1C, the right two bars of each panel). Thus,
lowering Gpr52 may rescue the Huntington’s disease-asso-
ciated phenotype in the open-ﬁeld tests, and the effects may
persist at older ages. Noticeably, Gpr52 knockout had no
effect in the wild-type mice (Fig. 1A–C), conﬁrming that
the rescue effects in Huntington’s disease mice were disease-
relevant. Similarly, Gpr52 heterozygous or homozygous
knockout rescued the rearing phenotype in the
Huntington’s disease mice at all the ages tested (Fig. 2A).
Another disease-relevant phenotype of Huntington’s dis-
ease patients that inﬂuences the life quality of many
Huntington’s disease patients is abnormal walking behav-
iour (Daneault et al., 2015), and thus we tested potential
walking phenotype of these Huntington’s disease mice by
the CatWalk gait analysis system, which captured videos of
walking behaviours and gaits of mice passing through a
lane. While Huntington’s disease mice exhibited some gait
and movement abnormalities around 7 months, the pheno-
type was much more obvious and robust at 10 months.
The Huntington’s disease mice showed signiﬁcantly more
frequent stops, trembles, head turns and irregular steps
compared to the wild-type mice. We thus quantiﬁed the
frequencies of these abnormal walking behaviours of
10-month-old mice as readout for Huntington’s disease
walking deﬁcits (Fig. 2B). Gpr52 + / or Gpr52/ signiﬁ-
cantly rescued these walking deﬁcits in Huntington’s dis-
ease mice without inﬂuencing the wild-type mice (Fig. 2B).
We also quantiﬁed the variation of the speed of each foot
and time spent passing the test lane, and Huntington’s dis-
ease mice exhibited larger variation of speed and longer
passing time, reﬂecting gait irregularities and deﬁcits.
Gpr52/ signiﬁcantly rescued these phenotypes in
Huntington’s disease mice, although Gpr52 + / had little
effect (Supplementary Fig. 1), likely because Gpr52/
may lead to stronger rescue effects on walking and gait
abnormalities than Gpr52 + /. Similar trends could be
observed in the open-ﬁeld and rearing tests (Figs 1A, B
and 2A).
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The rotarod performance is another widely accepted read-
out for motor functions inﬂuenced in Huntington’s disease.
At the age of 15 months, Huntington’s disease mice exhibit
evident motor function deﬁcits in the rotarod tests quanti-
ﬁed by the latency to fall (Fig. 2C). The Gpr52 knockout
Huntington’s disease mice (Gpr52/; HdhQ140/Q140)
showed signiﬁcant improvement of the rotarod performance
(Fig. 2C), conﬁrming the rescue of rotarod phenotype that
exhibited at late ages. Similar to other behavioural tests,
Gpr52 knockout had no effect on the wild-type mice
(Fig. 2C), suggesting that the rescue effects were
Huntington’s disease-speciﬁc.
Knockout of Gpr52 rescues
Huntington’s disease-associated
biomarkers in vivo
We then investigated whether Gpr52 knockout rescued
Huntington’s disease-associated molecular phenotypes,
Figure 1 Knockout of Gpr52 rescued Huntington’s disease-associated open-field phenotypes in a knock-in Huntington’s
disease mouse model. (A) Travel distances, cross numbers and central/peripheral ratios in the open-field tests of 7.5-month-old mice of
the indicated genotypes. Each dot represents an individual mouse, and each corresponding bar represents mean  standard error of the mean
(SEM). The statistical analysis was performed by one-way ANOVA and post hoc Bonferroni’s tests for the indicated comparisons. n.s. = not
significant = P4 0.1, *P5 0.05, **P5 0.01, ***P5 0.001, and ****P5 0.0001. P-values between 0.05 and 0.1 are presented by exact values.
Huntington’s disease mice showed significant lowering in the travel distance and cross number, which were rescued by Gpr52+ / or Gpr52/.
(B and C) As in A, but using 10-month-old or 13.5-month-old mice, respectively.
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which reﬂect Huntington’s disease cytoxicity in vivo.
Huntington’s disease neurodegeneration mainly inﬂuences
the medium spiny neurons in the striatal region, and the
level of medium spiny neuron marker DARPP-32 reﬂects
Huntington’s disease neurotoxicity (Hodas et al., 2012).
At 16 months of age, Huntington’s disease mice striata ex-
hibited a decreased level of DARPP-32, whereas the hetero-
zygous or homozygous knockout of Gpr52 signiﬁcantly
increased the DARPP-32 level (Supplementary Fig. 2A), sug-
gesting a rescue effect at the molecular level. Meanwhile,
Figure 2 Knockout of Gpr52 rescued Huntington’s disease-associated rearing, gait and rotarod phenotypes in a knock-in
Huntington’s disease mouse model. (A) Rearing number per 5min in the mouse of indicated genotypes (x-axis) at the indicated ages
(above each graph). Each dot represents an individual mouse, and each corresponding bar represents mean  SEM. (B) In the CatWalk gait
analysis tests, the number of stops, trembles and head turns of each trial were quantified based on the video captured. The averaged numbers
per trial were calculated based on three repeated trials for each mouse, and were then summarized based on the genotypes indicated in
the x-axis. Each dot represents an individual mouse, and each corresponding bar represents mean  SEM. (C) Rotarod test results for
15-month-old mice of indicated genotypes. Each mouse was trained for 3 days and then tested for five consecutive days. The mean  SEM of
the latency to fall (y-axis) of each genotype (colour) was plotted. The statistical analyses were performed by one-way ANOVA tests for A and B
and two-way ANOVA tests for C. n.s. = P4 0.1, *P5 0.05, **P5 0.01, ***P5 0.001, ****P5 0.001.
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Gpr52/ only slightly increased the DARPP-32 level in the
wild-type mouse striata, and the increase was not signiﬁcant
after normalizing to the loading control (b-tubulin), suggest-
ing that the effect is Huntington’s disease-speciﬁc.
Besides neurons, glial cells were also altered in
Huntington’s disease and signiﬁcant astrogliosis and micro-
gliosis are detected in the caudate nucleus and internal cap-
sule of Huntington’s disease patients, but not in the normal
brain (Dieterich et al., 2006). This phenomenon is likely
associated with the elevated neuroinﬂammation responses
in Huntington’s disease. While its functional signiﬁcance in
Huntington’s disease remains unclear, the relevant glia ac-
tivation markers have been widely used as indicators of
Huntington’s disease pathology (Kirkin et al., 2009; Yang
et al., 2017). We thus investigated GFAP and Iba1, which
are markers for astrocytes and microglia, respectively
(Kirkin et al., 2009). Consistent with previous studies,
Huntington’s disease mice exhibited elevated numbers of
GFAP+ and Iba1+ cells in the striata at 16 months of
age (Supplementary Fig. 2B), likely due to increased neu-
roinﬂammation in the context of mHtt expression.
Knocking-out Gpr52 signiﬁcantly reduced the GFAP+
cells and the Iba1+ cells in the Huntington’s disease but
not wild-type striata (Supplementary Fig. 2B), suggesting a
rescue effect.
Knockout of Gpr52 reduces soluble
and aggregated mHtt level in the
striata in vivo
We previously demonstrated that lowering GPR52 reduces
soluble mHtt protein levels in cellular Huntington’s disease
models and in the striata of HdhQ7/Q140 knock-in mice at
early ages (2 months) (Yao et al., 2015).
To test if the lowering mHtt effect persists in the homo-
zygous Huntington’s disease mice (HdhQ140/Q140) at old
age, we tested the soluble mHtt levels of mouse brain tis-
sues at 16 months of age. Consistently, heterozygous or
homozygous knockout of Gpr52 signiﬁcantly reduced sol-
uble mHtt levels in the striata but not the cortices (Fig. 3A).
In addition, the total ﬂuorescent signal of mHtt macro-ag-
gregates in Huntington’s disease mice at 10 months of age
were signiﬁcantly reduced by heterozygous knockout of
Gpr52, and almost absent in Gpr52 homozygous knockout
mouse striatal slices (Fig. 3B), probably as a consequence of
the reduction of soluble mHtt protein and prevention of
aggregate formation. This is also consistent with previous
Htt-targeting antisense oligonucleotide studies, which
showed ablation of mHtt aggregates after antisense oligo-
nucleotide treatment (Kordasiewicz et al., 2012). In sum-
mary, lowering Gpr52 reduced both soluble and aggregated
Htt levels in vivo.
We then assayed the Huntington’s disease neurodegen-
eration by counting the density of D1 and D2 dopamine
receptor-expressing neurons identiﬁed by in situ staining.
Signiﬁcant decrease of D1 and D2 neuron density was
observed in disease striatal slices, and knocking-out
Gpr52 signiﬁcantly rescued this phenotype (Fig. 3C), con-
sistent with the lowering mHtt.
Striatal expression of human Gpr52
restored mHtt levels and
Huntington’s disease-associated
phenotypes
To conﬁrm that the effect of Gpr52 knockout was
mediated by the loss of Gpr52, we tested whether the ex-
pression of Gpr52 cDNA in the striatum is able to restore
mHtt levels and Huntington’s disease-associated pheno-
types. We injected adeno-associated viruses (AAV) express-
ing human GPR52 (hGpr52) cDNA driven by a neuronal
promoter (the human synapsin 1 promoter) into both left
and right striata of the Gpr52 knockout Huntington’s dis-
ease mice (Gpr52/, HdhQ140/Q140), and managed to ex-
press hGpr52 in the striata (Supplementary Fig. 3A and B).
Compared to the control AAV (expressing EGFP) injected
mice, the hGpr52 expressing AAV signiﬁcantly increased
the soluble mHtt level 4.5 months after injection
(Supplementary Fig. 3A). Mutant Htt aggregate signals
were not signiﬁcantly changed (Supplementary Fig. 3C).
The number of GFAP+ cells and the number of Iba1+
cells in the Huntington’s disease striata were increased
(Supplementary Fig. 4A) whereas the DARPP-32 level re-
mained the same (Supplementary Fig. 4B), suggesting that
the Huntington’s disease-associated gliosis phenotype was
partially restored by increasing mHtt levels.
We then tested the hGpr52 AAV-injected Gpr52/,
HdhQ140/Q140 mice in the open-ﬁeld, rearing, gait and
rotarod tests, and examined different motor function-rele-
vant parameters. Three to 4.5 months after injection, the
hGpr52 cDNA AAV-injected mice exhibited Huntington’s
disease-associated behavioural deﬁcits in almost all the par-
ameters tested (Fig. 4 and Supplementary Fig. 5), compared
to the control AAV-injected mice. Only the travel distance
in the open-ﬁeld test and the passing time in the gait
analysis were not signiﬁcantly inﬂuenced by the hGpr52
cDNA AAV-injection in the Gpr52/, HdhQ140/Q140 mice
(Supplementary Fig. 5A and B). In summary, our data sug-
gest that most of the Huntington’s disease-associated be-
havioural phenotypes were restored by expressing hGpr52
via AAV injection, likely due to restoration of the mHtt
levels in the striata. The restoration of the Huntington’s
disease-associated phenotypes was not due to toxicity of
hGpr52, because none of the behavioural parameters
were signiﬁcantly inﬂuenced in the Gpr52/, HdhQ7/Q7
mice (Fig. 4B, Supplementary Fig. 5A and C), suggesting
that the effect was Huntington’s disease-speciﬁc.
The data above conﬁrm that the rescue of Huntington’s
disease-associated phenotypes by Gpr52 knockout was
mediated through the deletion of Gpr52, because the ex-
pression of hGpr52 in the striatum is able to restore mHtt
expression and Huntington’s disease deﬁcits. In addition,
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Figure 3 Knockout of Gpr52 reduced soluble and aggregated mHtt levels in striata of a knock-in Huntington’s disease mouse
model. (A) Representative western blot and quantification of mHtt protein levels in striata and cortices from 16-month-old mice of indicated
genotypes. Bars represent mean  SEM. Statistical analysis was performed by one-way ANOVA and post hoc Dunnett tests. n.s. = P4 0.1,
**P5 0.01. (B) Representative immunostaining and quantification of mHtt aggregates in striata slices from 10-month-old mice of indicated
genotypes. Scale bar = 50 mm. Bars represent mean  SEM; n indicates the number of different mice of each genotype. The image capture and
analyses were performed blindly before annotating the genotypes. Aggregation signal per cell was analysed by particle analysis in ImageJ and
calculated by: the number of aggregates  aggregate size  mean aggregate fluorescent intensity / cell number counted by DAPI. The statistical
analysis was performed by one-way ANOVA and post hoc Dunnett tests for the indicated comparisons: ****P5 0.0001. (C) Representative in situ
images and quantification of D1 or D2 positive neurons in striata slices from 16-month-old mice of indicated genotypes. Scale bar = 10 mm. Bars
represent mean  SEM; n indicates the number of different mice of each genotype. The statistical analysis was performed by one-way ANOVA and
post hoc Bonferroni’s tests for the indicated comparisons: *P5 0.05, ****P5 0.0001.
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the human and mouse Gpr52 have a conservative role in
regulating Htt.
A novel Gpr52 antagonist E7
decreases soluble mHtt levels
GPR52 regulates the mHtt level via its GPCR function
(Yao et al., 2015), and thus small molecule antagonists
blocking GPR52 activity may lower mHtt levels and treat
Huntington’s disease. Unfortunately, GPR52 antagonists
are completely unknown, although GPR52 compound
agonists have been reported previously (Setoh et al.,
2014). Thus, we carried out a compound screen to identify
novel GPR52 antagonists.
We generated a HEK293 cell line stably expressing myc-
tagged human GPR52. Western blots and immunoﬂuores-
cent staining with anti-myc antibody indicated the
Figure 4 hGpr52 cDNA AAV injection in the striatum restored Huntington’s disease-associated phenotypes in a knock-in
Huntington’s disease mouse model. (A) hGpr52 cDNA AAV injected Gpr52 knockout Huntington’s disease mice (Gpr52/; HdhQ140/Q140)
were tested in the indicated behavioural phenotypes and the parameters were analysed. Each dot represents an individual mouse, and each
corresponding bar represents mean  SEM. The statistical analysis was performed by two-tailed unpaired t-tests: *P5 0.05, **P5 0.01. For most
behavioural test parameters, hGpr52 cDNA AAV injection significantly restored the Huntington’s disease-associated behavioural deficits. (B) As in
A, but using Gpr52 knockout wild-type mice (Gpr52/; HdhQ7/Q7). (C) hGpr52 cDNA or control AAV injected Gpr52 knockout Huntington’s
disease (Gpr52/; HdhQ140/Q140) and wild-type (Gpr52/; HdhQ7/Q7) mice were tested in the rotarod tests. The statistical analysis was
performed by two-way ANOVA tests: n.s. = P4 0.1, ***P5 0.001.
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proper expression of GPR52 (Fig. 5A and B). GPR52 is
a Gs-coupled GPCR, and a reported GPR52 agonist
WO-459 {N-(2-hydroxyethyl)-3-methyl-1-[2-[3-(triﬂuoro
methyl)benzyl]benzothiophen-7-yl]-1H-pyrazole-4-carboxa-
mide} (Setoh et al., 2014) induced dose-dependent elevation
of intracellular cAMP in HEK293/GPR52 cells with EC50
value of 6.0  0.7 nM, but not in the parental HEK293
cells (Fig. 5C).
The initial screen was carried out with the cAMP assay
using HEK293/GPR52 cells. The cells were treated with
test compounds (30 mM) or DMSO (negative control) for
30min, and then stimulated by WO-459 (100 nM). Thirty
minutes later, cells were lysed for intracellular cAMP meas-
urements. We assessed the robustness of the screening assay
by Z0 factor, the normalized 3  SD window between the
negative and positive controls (Zhang et al., 1999). The Z0
value for the assay was 0.58, and the signal-to-background
ratio was 2.99, indicating that the assay was adequately
optimized (Fig. 5D). Approximately 40 000 compounds
from the Chinese National Compound Library were
screened and the representative data points were shown
in Fig. 5E. Among those compounds that showed inhibi-
tory effect in the primary screen, a compound designated
AD31E7 (E7) showed signiﬁcant inhibitory effect on
Figure 5 Identification of E7 as a novel GPR52 antagonist. (A) Western blot analysis of HEK293 cells transfected with empty vector or
stably expressing myc-hGPR52. (B) Immunofluorescent staining of HEK293 cells transfected with empty vector or stably expressing myc-hGPR52
with anti-myc antibody (red) and nuclear staining by Hoechst 33342 (blue). Scale bar = 10 mm. (C) Intracellular cAMP response (measured by
HTRF) in HEK293 cells stably expressing myc-hGPR52 or transfected with empty vector after WO-459 (a reported GPR52 agonist) stimulation.
Plots represent mean  SEM, n = 4, independently plated and treated wells. (D) Z0 factor determination. Replicates of positive (WO-459) and
negative (DMSO) signals were studied. Dashed lines indicate means  3 SD of 40 data points. Z0 value for the assay was 0.58 and the S/B ratio was
2.99. (E) Representative results of the primary screening of 40 000 compounds. HEK293/GPR52 cells were treated with test compounds at 30 mM
concentration and then stimulated with 100 nM WO-459. Intracellular cAMP levels were measured, and the change by WO-459 in each well was
normalized to the average change in the DMSO pretreated group (response %). The dashed line (20%) indicates the threshold used for the
primary screen. (F) Effect of E7 (100 mM) on WO-459 (100 nM)-stimulated cAMP in HEK293/GPR52 cells, or forskolin (FSK, 1mM)-stimulated
cAMP in HEK293 cells. Bars represent mean  SEM, n = 3, independently plated and treated wells. (G) Chemical structure of E7. (H) Dose-
response of purchased E7 on WO-459 (100 nM)-stimulated cAMP in HEK293/GPR52 cells, or forskolin (1 mM)-stimulated cAMP in HEK293 cells.
Plots represent mean  SEM, n = 3, independently plated and treated wells.
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WO-459-induced cAMP elevation in HEK293/GPR52 cells,
but did not affect forskolin-induced cAMP accumulation in
HEK293 cells, indicating a GPR52-speciﬁc effect (Fig. 5F).
The chemical structure of E7 is presented in Fig. 5G. E7
is a natural product with the chemical name (3S,4R,
8R,9E)-10-methyl-5-methylidene-6,14-dioxo-7,13-dioxatri-
cyclo[10.2.1.04,8]pentadeca-1(15),9-dien-3-yl (2Z)-2-methyl
but-2-enoate. Since compound collections are inherently
unstable, new E7 was purchased from Analyticon
Discovery (#NP-012321) and used for the further charac-
terizations. The newly purchased E7 displayed dose-de-
pendent inhibition of WO-459 (100 nM)-stimulated
cAMP in HEK293/GPR52 cells with an IC50 value of
12.0  0.7 mM, and did not affect forskolin-induced
cAMP in HEK293 cells (Fig. 5H), suggesting that E7
modulates cAMP levels via inhibiting Gpr52. The speciﬁ-
city of E7 was further tested against several Gs-coupled
GPCRs, including b2AR, GCGR and GLP-1R (Supplemen-
tary Fig. 6). E7 did not block cAMP elevation induced by
the activation of those GPCRs, conﬁrming that E7 does not
act on or downstream of heterotrimeric Gs. To validate
the experimental system, we tested the reported antagonists
of those receptors, and they displayed dose-dependent in-
hibition of their target GPCRs (Supplementary Fig. 6).
We then tested E7’s effect on HTT levels in several
Huntington’s disease models. To achieve accurate quantiﬁ-
cation of HTT levels of cells treated with E7 at a number of
different concentrations, we measured HTT levels by the
well-established homogeneous time resolved ﬂuorescence
(HTRF) assay (Weiss et al., 2009), and then conﬁrm the
results by western blots. The HTRF assay uses a terbium-
conjugated antibody (donor) and a D2-conjugated antibody
(acceptor) targeting the same protein, and the time resolved-
ﬂuorescence resonance energy Transfer (TR-FRET) (Mathis,
1993) occurs when the two antibodies come to close prox-
imity by binding with the same protein molecule. As a result,
the HTRF signals are proportional to the target protein con-
centration (Paganetti et al., 2009). The technology has been
successfully applied to the measurement of human or mouse
HTT levels in many studies (Weiss et al., 2009, 2012). In the
mouse striatal cell line (STHdhQ7/Q111) (Trettel et al., 2000),
E7 reduced Htt levels and the IC50 value was close to those
of Gpr52 inhibition (IC50 = 4.5mM, Fig. 6A). We utilized the
2B7/2166 antibody pair, which detects both mHtt and wild-
type HTT. The antibody pairs that detect mHtt speciﬁcally,
such as the 2B7/MW1 and the 2B7/3B5H10 antibody pairs,
do not work properly in these cells (Liang et al., 2014). In
Huntington’s disease patient iPSC-derived striatal neurons
generated as previously described (Yao et al., 2015), we
used the 2B7/3B5H10 antibody pair to measure mHTT
levels. E7 treatment signiﬁcantly reduced the mHTT level
in these neurons, with a maximum reduction achieved at
3.75mM (Fig. 6B). The observed reduction is not due to
cell loss, because we controlled the total protein concentra-
tion for the HTT measurement. In addition, the CellTiter-
Glo measurement indicates slight increase of the cell
number by the compound treatment (Supplementary Fig.
7A and B).
We then investigated E7’s effects in vivo. The behavioural
phenotype in Huntington’s disease Drosophila model was
rescued by loss-of-function of the Drosophila homologue of
Gpr52 (CG18314, dGpr52) (Yao et al., 2015). Consistent
with this, the transgenic mHTT level was reduced by
dGpr52 loss-of-function (Supplementary Fig. 7C), suggest-
ing a conserved regulatory pathway that justiﬁes the poten-
tial of using Drosophila models for E7 validation in vivo.
We thus fed the Huntington’s disease Drosophila with
E7-containing foods versus the DMSO-containing controls.
For each genotype and treatment group, the ﬂies were
distributed randomly in a number of different glass tubes
containing 15 ﬂies per tube. Treatment of 10 or 20 mM E7
for 6 days signiﬁcantly reduced mHTT levels in both the
full-length and the exon 1 Huntington’s disease models
(full-length HTT-Q128 and HTT-exon1-Q72, Fig. 6C).
Treatment of 5 mM E7 for 6 days signiﬁcantly reduced
mHTT levels in the exon1 Huntington’s disease model,
but not in the full-length model (Fig. 6C). In summary,
E7 can reduce mHtt levels in both models when sufﬁcient
dose is given.
Encouraged by the ﬂy data, we tested E7’s effect in
Huntington’s disease mice. Since it is unclear whether E7
can penetrate the mouse blood–brain barrier, we delivered
E7 directly into the mouse brain by intracerebroventricular
injection. We inserted and ﬁxed a capped plastic tunnel
through the skull of each mouse so that the injection
could be made repeatedly (see ‘Materials and methods’ sec-
tion and Supplementary Fig. 7F). E7 injection for 9 days
with one dose (2 ml at 2.5mM) per day signiﬁcantly
reduced mHtt levels in the striatum but not the cortices
based on the HTRF measurements (Fig. 6D). The reduction
in Huntington’s disease cells and tissues was also validated
by western blots (Supplementary Fig. 7D–F). E7 reduced
both mHtt and wild-type HTT level (Supplementary Fig.
7D and E), consistent with the effect of Gpr52 knockout.
To conﬁrm that the E7’s effect was mediated speciﬁcally
via Gpr52, we knocked-down Gpr52 in STHdhQ7/Q111
cells, and found that the E7’s effect on Htt largely
disappeared (Fig. 6E). Consistently, in cultured striatal neu-
rons from Gpr52 knockout Huntington’s disease mice
(Gpr52/, HdhQ7/Q140), the E7’s effect on Htt disappeared
as well (Fig. 6F). The data above conﬁrm that the E7’s
effect in reducing Htt was mediated by Gpr52.
Our previous data suggested that Gpr52 modulates HTT
protein levels but not mRNA levels (Yao et al., 2015).
However, this conclusion was not adequately tested
in vivo. More importantly, we did not examine the level of
an aberrant incomplete transcription of mutant HTT that
results in expression of mHTT-exon 1 protein particularly
in the striatum (Sathasivam et al., 2013). We thus tested
both the full-length and the incomplete exon 1–intron 1 tran-
scripts in the striata from E7 versus control-treated mice by
real time-quantitative PCR, and observed no signiﬁcant
change of these transcripts by E7 (Supplementary Fig. 8),
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suggesting that E7 regulates the mHTT level at the post-tran-
scriptional level.
The Gpr52 antagonist E7 rescues
Huntington’s disease relevant pheno-
types in human and mouse models
We then investigated whether E7 may have beneﬁcial
effects on Huntington’s disease-associated phenotypes by
lowering mHTT. If successful, E7 may provide the proof-
of-concept evidence for treating Huntington’s disease via
targeted small molecule compounds that lowers mHTT,
or even a candidate lead compound that could be de-
veloped into a Huntington’s disease drug.
Huntington’s disease patient iPSC-derived neurons exhibit
elevated apoptosis, shrinkage and loss of processes under
stress conditions such as withdrawn of the brain-derived
neurotrophic factor (BDNF) (HD-iPSC-Consortium, 2012;
Lu et al., 2013). These phenotypes are mHTT-dependent
and could be used as readout for assaying Huntington’s dis-
ease-associated cytotoxicity (Lu and Palacino, 2013; Yao
et al., 2015). In the Huntington’s disease patient iPSC-derived
striatal neurons (Q47), the apoptosis phenotype could be
Figure 6 A novel Gpr52 antagonist E7 reduced mHtt levels. (A) HTT levels in STHdhQ7/Q111 treated for 2 days with different doses of
E7 were measured by 2B7/2166 HTRF. Six independently plated and treated wells were tested for each dose of each compound. The plots
(mean  SEM) were fitted with the Boltzmann curve. (B) mHTT levels in Huntington’s disease patient iPSC-derived neurons (Q47) treated with
the indicated concentrations of E7 were measured by 2B7/3B5H10 HTRF. The number in each bar represents the number of independently plated
and treated wells. (C) mHTT levels in fly head lysates from elav-GAL4 driven transgenic Drosophila expressing full-length human mHTTwith 128Q
(full-length HTT-Q128) or mHTT-exon1 fragments with 72Q (HTT-exon1-Q72) fed for 6 days with E7 or the DMSO control at the indicated
concentrations in the food. mHTT levels were measured by 2B7/3B5H10 HTRF. n indicates the number of independent vials containing 15 virgin
female flies in each vial. (D) Mutant Htt levels in the E7 versus vehicle control (DMSO) intracerebroventricularly-injected mouse brain tissues.
Mutant Htt levels were measured by 2B7/2166 HTRF. Both the striata and the cortices were tested after 9 days of injection. Six mice in each group
were measured. (E) Similar as the E7 treatment in (A), but the cells were transfected with the non-targeting (Neg_si) or the Gpr52 siRNA
(Gpr52_si) 2 days before E7 treatment. Gpr52 knock-down abolished E7’s effect. (F) The cultured primary striatal neurons from neonatal mice
with the indicated genotypes were treated with the indicated concentrations of E7, and their Htt levels were measured by the 2B7/2166 HTRF 2
days after treatment. Six independently plated and treated wells are tested. All bar plots represent mean  SEM. Statistical analyses were
performed by two-tailed unpaired t-tests (D) or one-way ANOVA and Dunnett’s post hoc tests (B, C and F) for indicated comparisons:
n.s. = P4 0.1, *P5 0.05; **P5 0.01; ****P5 0.0001.
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measured by assaying the caspase-3 activity with the ﬂuores-
cent dye (Supplementary Fig. 9A), and the neuronal shrink-
age and processes loss phenotype could be measured by
immunostaining for Tuj1, a neuronal-speciﬁc-tubulin that
captures neuronal morphology (Fig. 7A). Treatment of E7
at the optimal dose signiﬁcantly rescued both phenotypes
(Fig. 7A and Supplementary Fig. 9A), conﬁrming E7’s effect
on Huntington’s disease-associated phenotypes at the cellular
level.
To conﬁrm E7’s effect in vivo, we ﬁrst examined the
climbing behavioural phenotype in the Huntington’s dis-
ease transgenic ﬂies expressing full-length mHTT. Feeding
with foods containing 10 mM E7 signiﬁcantly rescued the
climbing deﬁcits in Huntington’s disease ﬂies and had no
effect in the ﬂies expressing wild-type HTT (Fig. 7B), con-
ﬁrming E7’s rescue effect at the behavioural level. Flies
expressing the mHTT-exon 1 fragment exhibited similar
climbing deﬁcits and a shorter lifespan, and these pheno-
types were also rescued by feeding with E7-containing food
(Fig. 7C). We thus further examined the cellular and motor
function phenotypes of E7-treated mice. In 8.5-month-old
Huntington’s disease mice (HdhQ140/Q140), E7 injection for
9 days signiﬁcantly reduced mHtt aggregates in the stri-
atum (Fig. 8A). The number of GFAP+ and the number
of Iba1+ cells were both reduced as well (Supplementary
Fig. 9B), suggesting the Huntington’s disease-associated
gliosis phenotype was partially rescued by E7 injection.
In the rearing and open-ﬁeld tests, intracerebroventricular
injection of E7 for 9 days with one dose per day to
8.5-month-old mice signiﬁcantly improved the motor func-
tion performance in the Huntington’s disease mice, and had
no inﬂuence on the wild-type mice (Fig. 8B and C), con-
ﬁrming E7’s rescue effect in vivo. In all the experiments
described above, we investigated the rescue of mouse
Figure 7 A novel Gpr52 antagonist E7 rescued Huntington’s disease-associated phenotypes in cells and flies. (A) Images:
representative immunostaining results of neuronal specific tubulin marker Tuj1and DAPI showing neuronal morphology of patient iPSC-derived
striatal neurons (Huntington’s disease: Q47; wild-type: Q19). Loss of processes and shrinkage of neurons could be observed in Huntington’s
disease neuronal after BDNF removal. Scale bar = 100 mm. Bar plots: quantification of the Tuj1 signal covered area (Tuj1 area) normalized to the
nuclei counts. The lower Tuj1 area per cell reflects neuronal processes shrinkage and loss. Data were normalized to the wild-type control. The
statistical analysis was performed by one-way ANOVA with post hoc Dunnett’s tests: ****P5 0.0001. (B) Virgin female flies with indicated
genotypes and treatment were placed in different vials and tested in the climbing behavioural assay. Q128: full-length HTT-Q128 driven by elav-
GAL4, n = 4 for both DMSO and E7 (10mM) treated groups; Q16: full-length HTT-Q16 driven by elav-GAL4, n = 3 for both DMSO and E7 (10mM)
treated groups. n indicates the number of different batches of flies, which were place in different vials at 15 flies (virgin female) per vial. Data were
plotted as mean  SEM, and the statistical analysis was performed by two-way ANOVA tests. ***P5 0.001, ****P5 0.0001. (C) Left: As in B, but
using flies expressing HTT-exon1 fragments with indicated Q lengths. The statistical analysis was performed by two-way ANOVA tests.
***P5 0.001, ****P5 0.0001. Right: survival curves of the flies expressing HTT-exon1 fragments treated with the indicated compounds.
The statistical analysis was performed by the log-rank test. ***P5 0.001, ****P5 0.0001.
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Figure 8 A novel Gpr52 antagonist E7 rescued Huntington’s disease-associated phenotypes in mice. (A) Representative
immunofluorescent images (by the antibody S830) (scale bar = 100 mm), and quantifications of mHtt aggregates in Huntington’s disease mouse
striatal slices from mice intracerebroventricular-injected with E7 or vehicle control. The quantification was performed in the same way as in
Fig. 3B. The statistical analysis was performed by two-tailed unpaired t-tests: *P5 0.05. (B) Rearing test results of the E7 versus vehicle control
intracerebroventricularly-injected wild-type (left) or Huntington’s disease mice (right). The mice (8.5 months of age) were intracerebroventri-
cularly injected for 9 days before the behavioural tests and brain tissue extraction (Fig. 6D). Each dot represents an individual mouse. Bar plots
represent mean  SEM. Statistical analysis was performed by two-tailed unpaired t-tests: n.s. = P4 0.1, **P5 0.01. E7 had no effect in the
wild-type mice and significantly rescued Huntington’s disease mice. (C) As in B, but for open-field tests. The statistical analysis was performed by
two-tailed unpaired t-tests: n.s. = P4 0.1, *P5 0.05, **P5 0.01. (D) Rotarod test results of the E7 versus vehicle control intracerebroventri-
cularly-injected 15-month-old heterozygous Huntington’s disease mice (HdhQ7/Q140 mice injected for 7 days, trained for 3 days and then tested for
5 days; the one injection per day was continued during training and testing days). The statistical analysis was performed by two-way ANOVA tests.
****P5 0.0001. (E) Representative immunofluorescent images of NFL (scale bar = 10 mm) and quantifications of neurofilament light chain (NFL)
in wild-type and Huntington’s disease mouse striatal slices from mice intracerebroventricularly-injected with E7 or vehicle control. The NFL
signals were normalized by the number of cells (counted by DAPI). The statistical analysis was performed by one-way ANOVA and Bonferroni’s
post hoc tests for indicated comparisons: n.s. = P4 0.1, **P5 0.01, ****P5 0.001.
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behavioural phenotypes in homozygous Huntington’s
disease mice (HdhQ140/Q140), because their phenotypes
were more robust at earlier ages (before 12 months old).
To conﬁrm the effect in heterozygous Huntington’s dis-
ease mice (HdhQ7/Q140), we further tested E7’s effect in
HdhQ7/Q140 mice at the age of 15 months, because these
mice had the genotype closest to the real Huntington’s dis-
ease patients. Intracerebroventricularly-injected E7 signiﬁ-
cantly rescued the rotarod deﬁcits of these mice (Fig. 8D),
conﬁrming the therapeutic potential of targeting Gpr52.
Finally, we assayed Huntington’s disease neuronal
damage by immunostaining of the neuroﬁlament light
chain (NFL), which exhibited signiﬁcant loss in disease stri-
atal slices, and this was partially rescued by E7 injection
(Fig. 8E).
Discussion
Gpr52 as a Huntington’s disease drug
target
Our current study provides two major pieces of evidence
for in vivo establishing Gpr52 as a Huntington’s disease
drug target: lowering mHtt and rescuing Huntington’s dis-
ease-associated phenotypes. We conﬁrmed the effect by
both the genetic deletion and the compound antagonist.
In addition, we showed that expressed of hGpr52 restored
the mHtt levels and Huntington’s disease-associated pheno-
types, conﬁrming that the knockout effect is on target.
From 40000 compounds, we identiﬁed one relatively spe-
ciﬁc Gpr52 antagonist (Fig. 5 and Supplementary Fig. 6), E7,
which functioned as expected in lowering mHtt and rescuing
Huntington’s disease-associated phenotypes (Figs 6–8). In
addition, E7 likely modulates mHtt levels via inhibiting
Gpr52: knocking-down or knocking-out Gpr52 abolished
the effect of E7 in lowering Htt (Fig. 6E and F). Given the
EC50 of WO-459 (Fig. 5C) and the IC50 of E7 in inhibiting
Gpr52 with treatment of agonist (100nM WO-459,
Fig. 5H), the Ki of E7 for Gpr52 was roughly estimated to
be 0.9mM using the Cheng-Prussof equation (Lazareno and
Birdsall, 1993). The range is largely consistent with the ef-
fective concentrations of E7 in lowering mHtt levels (Fig. 6).
E7 was active mainly in the Huntington’s disease genetic
background (Figs 6–8), and this might reﬂect that Gpr52
might have enhanced activation in Huntington’s disease, pos-
sibly due to an increase in the concentration of its agonist.
Our previous studies have demonstrated that Gpr52
modulates Htt levels via a cAMP-dependent but PKA-inde-
pendent pathway (Yao et al., 2015), and this is consistent
with previous chemical–genetics studies (Williams et al.,
2008). In addition, we demonstrated that the effect was
mediated by enhanced proteasomal degradation of mHtt
via inactivation of the small GTPase Rab39B (Yao et al.,
2015). While the impact of cAMP pathway in Huntington’s
disease is complicated and we cannot exclude other
mechanisms mediating Gpr52’s effect, the fact that target-
ing Gpr52 by genetic deletion or an antagonist signiﬁcantly
lowers mHtt and rescues Huntington’s disease phenotypes
is convincing to justify Gpr52 as a potential Huntington’s
disease target.
Regarding safety, the physiological function of endogen-
ous Gpr52 remains unclear. In our study, we observed no
behavioural phenotypes in Gpr52 knockouts in the wild-
type background. We observed no change in the animal
size, weight and major organ morphology by Gpr52
knockout in both the wild-type and Huntington’s disease
background (not shown). The previously reported Gpr52
homozygous knockout generated in another background
(129SvEv) exhibited no obvious phenotypes and no
change in brain morphology (Komatsu et al., 2014).
There was no change in the travel distance in the open-
ﬁeld tests (Komatsu et al., 2014), consistent with our
observation (Fig. 1). They exhibited higher frequency of
startle but not prepulse inhibition behaviours when treated
with the NMDA receptor antagonist MK-801 (Komatsu
et al., 2014), and enhanced the locomotor-stimulating
effect of the ADORA2A antagonist istradefylline but not
methamphetamine MK-801 (Hancock et al., 2012). The
only behavioural phenotypes of the 129SvEv Gpr52 knock-
out model without compound treatment were the increased
time staying in the central region in the open-ﬁeld test
(Komatsu et al., 2014) and the increased novelty-induced
locomotor activity (Hancock et al., 2012). These two
phenotypes might be somewhat inconsistent with our
observation (Figs 1–2), possibly due to different genetic
background and test conditions (age, equipment, etc.). In
addition, the method to generate the Gpr52 knockout was
different, and the Gpr52 knockout mice in the previous
Gpr52 knockout study have kept the LacZ and neomy-
cin-resistant gene cassette, which may induce artefacts.
Nonetheless, inhibiting Gpr52 by E7 or other antagonist
may interfere with the dopamine circuits via inﬂuencing
intracellular cAMP and induce phenotypes under certain
conditions such as schizophrenia. Special cautions should
be given for patients with these conditions when treated
with Gpr52 antagonists. Meanwhile, E7 treatment in
the Huntington’s disease mice did not inﬂuence
prepulse inhibition or new-objective recognition phenotypes
(Supplementary Fig. 10), suggesting that E7 treatment may
not lead to psychotic or cognitive defects.
Lowering mHtt as a potential
strategy for Huntington’s disease
treatment
Lowering mHtt protein levels is considered as the most
promising strategy for Huntington’s disease treatment. In
fact, a clinical trial aiming at lowering Htt levels by anti-
sense oligonucleotides has already been launched. While
such strategies using RNA-like molecules targeting mRNA
are certainly promising and of great importance in the ﬁeld,
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their delivery is still highly challenging and their cost are
unacceptable for most Huntington’s disease patients. Thus,
small molecule compound drugs are highly desired. Gpr52
and its antagonist E7 provide new avenues for discovery of
such drugs that may modify Huntington’s disease progres-
sion via lowering mHtt protein level.
Mutant Htt lowering per se is likely the major mechan-
ism that mediates the effect of Gpr52 on Huntington’s
disease-associated phenotypes. Compelling evidence has
shown that reducing mHtt by many different approaches
can rescue the Huntington’s disease-associated phenotypes
(Yu et al., 2014), and Gpr52 signiﬁcantly reduces mHtt
levels in all striatal Huntington’s disease models tested.
Importantly, Gpr52 or E7 does not inﬂuence the pheno-
types in the wild-type mice (Figs 1, 2, 4 and 8). In addition,
knocking-down Gpr52’s downstream modulator Rabgap1l
largely abolished its rescue effect in patient iPSC-derived
striatal neurons (Yao et al., 2015), conﬁrming that the
rescue was mediated through lowering mHtt, at least at
the cellular level. Interestingly, expression of hGpr52
cDNA using a neuron-speciﬁc promoter restored the in-
crease of Iba1+ or GFAP+ glial cells in the Huntington’s
disease mice (Supplementary Fig. 4A). Injection of the
Gpr52 antagonist E7 for 9 days signiﬁcantly reduced
Iba1+ or GFAP+ glial cells in the Huntington’s disease
mice as well (Supplementary Fig. 9). The data suggest
that a short-term lowering of the neuronal mHtt level is
sufﬁcient to reduce neuroinﬂammation related gliosis,
potentially through non-cell autonomous mechanisms.
Contribution of striatal mHtt to
Huntington’s disease
One common characteristic of Huntington’s disease and
most other neurodegenerative disorders is that the neuro-
degeneration occurs quite selectively in certain brain re-
gions. This regional selectivity is especially intriguing in
Huntington’s disease, because the disease-causing protein
mHtt is widely expressed, while the neurodegeneration
mainly inﬂuences in the striatum, especially at early stages
(Raymond et al., 2011). One potential possibility is that
striatal cells express speciﬁc genes that enhance mHtt tox-
icity or stabilizes mHtt (Blum et al., 2003; Thomas, 2006;
Subramaniam et al., 2009). In fact, the mHtt turnover rate
is slower in the striatal neurons compare to cortical neu-
rons (Tsvetkov et al., 2013), likely because of striatal-en-
riched mHtt stabilizers.
Gpr52 expression is striatal-enriched in mice (Komatsu
et al., 2014). The microarray data from Allen Brain Atlas
(www.brain-map.org) and our immunohistochemistry re-
sults from post-mortem brain slices conﬁrmed the striatal-
enriched expression of Gpr52 in the human brain as well
(Supplementary Fig. 11). Our study used a knock-in
Huntington’s disease model expressing endogenous mHtt,
and targeting Gpr52 mainly modulates striatal mHtt
(Fig. 3). The lowering of striatal mHtt by targeting
Gpr52 rescued Huntington’s disease-associated behavioural
phenotypes (Figs 1 and 2), whereas hGpr52 cDNA expres-
sion restored striatal mHtt levels and restored Huntington’s
disease-associated phenotypes (Fig. 4 and Supplementary
Fig. 3), conﬁrming contributions of striatal mHtt in
Huntington’s disease pathogenesis at least in the knock-in
model. Our data were also consistent with recent genome-
editing study, which showed that lowering striatal mHtt by
CRISPR/Cas9 signiﬁcantly rescued behavioural phenotypes
of the knock-in Huntington’s disease mice (Yang et al.,
2017).
The Gpr52 antagonist E7 and its
delivery by intracerebroventricular
injection
Importantly, the HTT-lowering effects and the rescue of
Huntington’s disease-associated phenotypes by targeting
Gpr52 have been validated cross-species in ﬂy, mouse and
human models (Figs 6–8). The cross-species validation may
increase the success rate of targeting Gpr52 in human pa-
tients, which are impossible to test in preclinical studies.
While RNA-targeting molecules such as antisense oligo-
nucleotides are also promising drug candidates to lower
mHTT, their delivery is highly challenging and their costs
are expensive. This is hard to be fundamentally improved
because of their intrinsic nature of being RNA-like large
molecules. In contrast, small molecule compound antagon-
ists for Gpr52 have much higher potential to be structurally
modiﬁed to a compound for easier delivery, although E7
per se may not be ready such purpose yet, because struc-
tural–activity relationship studies and pharmacokinetics/
pharmacodynamics studies are needed. Meanwhile, E7 pro-
vides a tool for the proof-of-concept study to demonstrate
the potential of targeting Gpr52.
In our current study, we delivered E7 by intracerebroven-
tricular injection, which we believe is an ideal approach for
proof-of-concept studies of novel compounds. Delivery by
other approaches such as intraperitoneal injection and
intravenous injection are closer to clinical use, but the re-
sults could be hard to interpret. Negative outcome could be
due to failure of passing the blood–brain barrier and/or
pharmacokinetics/pharmacodynamics issues. In addition, a
much larger amount of compound is needed for these
approaches compared to intracerebroventricular injection,
because the former approaches deliver the compound to
the whole body.
Many further steps are needed to develop Gpr52 antag-
onists for clinical use. E7 is currently active only in the
micromolar range, and the structure–activity relationship
studies of E7 and its structural analogues are desirable to
discover better compounds. Noticeably, E7 is a racemate
containing two enantiomers. Revealing the Gpr52-antago-
nizing and mHTT-lowering activity of both enantiomers is
highly desired for drug discovery purposes, although this is
technically challenging at this point, because neither of
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these enantiomers with sufﬁcient purity and quality are
available. Additional screening with larger libraries may
be desired for better compounds.
Once a high-efﬁcacy compound has been identiﬁed by
optimizing the structure of E7 or additional screening, the
compound will be tested for its penetration of the blood–
brain barrier, its pharmacokinetics/pharmacodynamics
properties and its safety proﬁles for further drug discovery
purposes.
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